1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Biosynex S.A.

Biosynex S.A.

ALBIO.PA
Biosynex S.A.undefined flagEuronext Paris
0.89
EUR
-0.01
- -
16.44MMarket Cap
Biosynex S.A.
ALBIO.PA
(Euronext Paris)

Recent

price

0.89

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.77
0.8
1.07
1.2
2.09
1.31
2.76
2.76
2.82
3.18
14.26
30.62
15.86
7.17
9.41
6.59
Revenue per Share
-0.02
-0.25
-0.51
-1.16
-0.78
-0.05
-0.01
0.03
0.05
0.1
2.91
8.32
1.26
-2.85
-4.03
-4.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.93
8.79
0.4
-0.74
-0.94
-0.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.65
- -
- -
- -
Dividend per Share
0.02
-0.19
-0.67
-1.79
-2.15
-0.55
-0.38
-0.34
0.13
0.18
2.99
10.56
6.29
0.08
-4.18
-3.77
Book Value per Share
-0.03
3.35
3.2
2.29
1.27
1.38
-0.04
0.35
0.41
0.12
3.25
9.26
6.46
-0.54
-3.02
-2.68
Tangible Book Value per Share
1
1
1
2
2
8
10
11
11
11
11
12
12
13
11
14
Basic Weighted Avg Shares
1
1
2
2
4
10
27
31
31
35
154
383
197
93
101
95
Sales/Revenue/Turnover
-8.49
-41.19
-49.8
-54.35
-16.92
-6.19
2.96
3.07
1.19
4.59
29.69
36.89
17.83
-40.23
-35.91
-66.54
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
7
2
21
13
21
53
Depreciation Expense
- -
- -
-1
-2
-2
- -
- -
- -
1
1
31
104
16
-37
-43
-58
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.7
27.38
23.59
28.76
- -
- -
- -
Effective Tax Rate (%)
-2.87
-31.08
-47.13
-96.51
-37.55
-3.69
-0.44
1.03
1.74
3.12
20.38
27.19
7.96
-39.74
-42.83
-61.16
Profit Margin (%)
- -
5
3
3
2
2
7
10
9
10
44
137
127
57
27
27
Working Capital
- -
- -
2
2
2
3
7
6
5
10
16
35
52
66
62
61
LT Debt
- -
5
5
4
3
21
24
29
29
31
66
168
167
124
80
35
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.74
47.43
66.58
11.08
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
13.53
105.46
96.91
10.61
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
63.27
182.9
126.65
14.92
-93.46
-4,027.14
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.19%
7.05%
-56.58%
Free Cash Flow
- -
-36.11%
-41.81%
Net Income, GAAP
236.42%
-27.55%
34.36%
Sales/Revenue/Turnover
58.95%
10.03%
-5.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
93
2024
- -
- -
- -
- -
101
2025
- -
- -
- -
- -
95

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.85
2024
- -
- -
- -
- -
-4.03
2025
- -
- -
- -
- -
-4.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Eurofins-Cerep S.A. (ALECR.PA)
DermTech, Inc. (DMTK)
Adicon Holdings Limited (9860.HK)
Genetic Technologies Limited (GENE)
DNA Chip Research Inc. (2397.T)
IGEA Pharma N.V. (IGPH.SW)
Business
Biosynex SA designs, manufactures and distributes rapid diagnostic tests (RDTs), point-of-care (POC) solutions, molecular biology assays and self-tests for in vitro diagnostics targeting healthcare professionals and consumers; its core portfolio encompasses tests for infectious diseases including bacteriology, parasitology, virology, mycology and COVID-19, women's health products for pregnancy, fertility and sexually transmitted infections, emergency markers, autoimmunity, biochemistry, oncology and tropical diseases such as malaria and tetanus, alongside instruments and immunoblots like Amnioquick, Immunoquick Malaria Falciparum, Immunoquick Elifa HSV IGG and Immunoquick Filtration CELIAC IgA; the company operates through subsidiaries including Chembio Diagnostics, ProciseDx for therapeutic drug monitoring, Medkoncept AS and distribution partners like Fumouze Diagnostics and SR2B. Founded in 2005 and headquartered at 22 Boulevard Sébastien Brant in Illkirch-Graffenstaden, France, Biosynex serves pharmacists, laboratories, doctors, hospitals and pharmacies across more than 90 countries with a focus on screening, diagnosis, prevention and patient care in resource-limited settings. Recent developments include a successful capital increase in February 2025, acceleration of group reorganization announced with 2024 annual results in April 2025 showing revenue growth from exports, FDA breakthrough device designation in June and July 2025 for key products, first-half 2025 revenue of 50.8 million euros reported in July 2025 despite a 6% decline, and initiation of safeguard proceedings in September 2025 to restructure operations alongside earlier acquisitions of ProciseDx in 2023, Chembio Diagnostics in 2023, a 75% stake in Medkoncept AS in January 2023 and Parakito in 2022.